Trillium and Genentech in global licence agreement

Published: 14-Dec-2004

Canadian biopharmaceutical company Trillium Therapeutics (TTI) has entered into an agreement with Genentech granting the latter exclusive worldwide rights to TTI's technology to develop and commercialise products directed against a particular but undisclosed target.


Canadian biopharmaceutical company Trillium Therapeutics (TTI) has entered into an agreement with Genentech granting the latter exclusive worldwide rights to TTI's technology to develop and commercialise products directed against a particular but undisclosed target.

Under the terms of the agreement, TTI will receive an upfront payment, research funding and milestone payments, as well as royalties on product sales in the event of commercialised products. No other financial terms were disclosed.

The companies will together complete preclinical development activities, while Genentech will be solely responsible for clinical development, regulatory approvals, manufacturing and commercialisation.

TTI currently has three programmes, two targeting the CD200 immunoregulatory axis and a third that focuses on pro-inflammatory cytokine receptor antagonists. The company has a broad network of external academic and industry r&d collaborations.

  

You may also like